Luhan Pharmachem Co., Ltd.

Luhan pharmachem Co., Ltd. supplies Crisaborole bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Crisaborole?

Crisaborole is a non-steroidal, topical medication approved for the treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older. As of 2016 it is also under development by Anacor Pharmaceuticals for the topical treatment of psoriasis.

Mechanism of action

It is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation. Chemically, crisaborole is a phenoxybenoxaborole. It contains a boron atom that helps penetrate the skin and is essential for its binding activity. Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.

Adverse effects

Serious adverse events include hypersensitivity reactions. The most frequent common adverse effect is pain at the site of application, including burning or stinging.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.